GlassScriptPhysician profile
Allen W Vander
NPI 1669473054
$1,472.83
in general payments reported to CMS, 2019-2025
14 companies · $310 in 2025
The $310 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.06 · 2020: $127 · 2021: $344 · 2022: $219 · 2023: $76.19 · 2024: $300 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $686.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $426.05 | 2024-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals LP | $252.62 | 2020-2024 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $196.29 | 2019-2023 | Jynarque |
| Akebia Therapeutics INC | $187.32 | 2019-2024 | Vafseo, Auryxia |
| Bayer Healthcare Pharmaceuticals INC. | $67.15 | 2021-2025 | |
| Vifor Pharma, INC. | $63.49 | 2020-2025 | Veltassa |
| Aurinia Pharma U.S., INC. | $62.97 | 2021-2022 | |
| Calliditas Therapeutics US INC. | $61.46 | 2022-2024 | |
| Opko Pharmaceuticals, LLC | $47.84 | 2020-2025 | Rayaldee |
| Amgen INC. | $44.64 | 2021 | |
| Scpharmaceuticals INC. | $19.09 | 2025 | |
| Alexion Pharmaceuticals, INC. | $17.23 | 2023 | Ultomiris |
| Daiichi Sankyo INC. | $14.45 | 2020 | |
| Novartis Pharmaceuticals Corporation | $12.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allen Vander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.